• Alnylam highlighted new analyses from HELIOS-B Phase 3 trial of vutrisiran in ATTR-CM, with results already presented at Heart Failure 2026.
• Analyses showed clinical benefit remained consistent across harder-to-treat patient groups, including those with atrial fibrillation, low systolic blood pressure, or higher overall disease burden, supporting positioning as a first-line option.
• Benefits also held up in patients using common background therapies, including ATTR stabilizers or standard heart-failure drugs, strengthening case for broad real-world use.
• Separate pooled safety analysis across more than 25,000 patient-years of exposure for vutrisiran and patisiran found low rates of vitamin A deficiency-related eye events, comparable to placebo, easing a key monitoring concern for TTR-lowering therapy.
• Company also outlined DemonsTTRate, a prospective observational study expected to enroll more than 2,000 ATTR-CM patients for up to five years to track real-world outcomes, treatment patterns, and healthcare utilization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260511111257) on May 12, 2026, and is solely responsible for the information contained therein.